Pregnancy can be a dangerous trigger for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), or hemolysis, elevated liver enzymes and low platelet (HELLP) syndrome. Due to the possibility of several serious complications, pregnancy is somewhat discouraged in the presence of the above diseases. Eculizumab is a humanized antibody that may dramatically change the clinical course of PNH, aHUS and HELLP syndrome. However, data on the safety of eculizumab in pregnancy are scarce. In this narrative overview, we summarize current evidence on the use of eculizumab during pregnancy in women with PNH, aHUS and HELLP syndrome. Eculizumab is not present in breast milk, and the levels observed in umbilical cord blood samples are not sufficient to affect the concentrations of complement in newborns. Therefore, eculizumab may be regarded as safe in pregnancy. Nonetheless, given that data on eculizumab in pregnancy are limited, it is not possible to completely exclude risks for both mother and fetus in treating PNH, aHUS and HELLP syndrome.
This is a preview of subscription content, log in to check access.
Compliance with ethical standards
Conflict of interest
All authors declare that they do not have conflict of interest.
Authors of papers that have been cited in the present review have declared that their studies have been approved by the appropriate institutional and/or national research ethics committee and have been performed in accordance with ethical standards.
There is no requirement for an informed consent form, this manuscript being a literature review.
Hashira S, Okitsu-Negishi S, Yoshino K (2000) Placental transfer of IgG subclasses in a Japanese population. Pediatr Int 42:337–342CrossRefGoogle Scholar
Kelly RJ, Höchsmann B, Szer J et al (2015) Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 373:1032–1039CrossRefGoogle Scholar
Takeda J, Miyata T, Kawagoe K et al (1993) Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 73:703–711CrossRefGoogle Scholar
Kinoshita T, Ohishi K, Takeda J (1997) GPI-anchor synthesis in mammalian cells: genes, their products, and a deficiency. J Biochem 122:251–257CrossRefGoogle Scholar
Danilov AV, Smith H, Craigo S et al (2009) Paroxysmal nocturnal hemoglobinuria (PNH) and pregnancy in the era of eculizumab. Leuk Res 33:2008–2009CrossRefGoogle Scholar
Fieni S, Bonfanti L, Gramellini D et al (2006) Clinical management of paroxysmal nocturnal hemoglobinuria in pregnancy: a case report and updated review. Obstet Gynecol Surv 61:593–601CrossRefGoogle Scholar
Ray J, Burows R, Ginsberg J, Burrows E (2000) Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: review and recommendations for management of the pregnant and nonpregnant patient. Hemostasis 30:103–117Google Scholar
de Guibert S, de Latour RP, Varoqueaux N et al (2011) Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience. Hematologica 96:1276–1283CrossRefGoogle Scholar
Sharma R, Keyzner A, Liu J et al (2015) Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis. Leuk Res Rep 4:36–38Google Scholar
Patriquin C, Leber B (2015) Increased eculizumab requirements during pregnancy in a patient with paroxysmal nocturnal hemoglobinuria: case report and review of the literature. Clin Case Rep 3:88–91CrossRefGoogle Scholar
Gessoni G, Canistro R, Bergamini L et al (2015) Postpartum thrombotic complication in a patient with paroxysmal nocturnal hemoglobinuria. Blood Coagul Fibrinolysis 26:458–463CrossRefGoogle Scholar
Miyasaka N, Miura O, Kawaguchi T et al (2016) Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review. Int J Hematol 103:703–712CrossRefGoogle Scholar
Patel A, Unnikrishnan A, Murphy M et al (2017) Paroxysmal nocturnal hemoglobinuria in pregnancy: a dilemma in treatment and thromboprophylaxis. Case Rep Hematol 2017:1–3Google Scholar
Vekemans MC, Lambert C, Ferrant A et al (2015) Management of pregnancy in paroxysmal nocturnal hemoglobinuria on long-term eculizumab. Blood Coagul Fibrinolysis 26:464–466CrossRefGoogle Scholar
Marasca R, Coluccio V, Santachiara R et al (2010) Pregnancy in PNH: another eculizumab baby Kelly. Br J Hematol 150:707–708CrossRefGoogle Scholar
Gaggl M, Aigner C, Csuka D et al (2017) Maternal and fetal outcomes of pregnancies in women with atypical hemolytic uremic syndrome. J Am Soc Nephrol 29:1020–1029Google Scholar
Dashe JS, Ramin SM, Cunningham FG (1998) The long-term consequences of thrombotic microangiopathy (thrombotic thrombocytopenic purpura and hemolytic uremic syndrome) in pregnancy. Obstet Gynecol 91:662–668Google Scholar
Fakhouri F, Vercel C, Frémeaux-Bacchi V (2012) Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy. Clin J Am Soc Nephrol 7:2100–2106CrossRefGoogle Scholar
Demir E, Yazici H, Ozluk Y et al (2016) Pregnant woman with atypical hemolytic uremic syndrome delivered a healthy newborn under eculizumab treatment. Case Rep Nephrol Dial 6:143–148CrossRefGoogle Scholar
Ardissino G, Ossola MW, Baffero GM et al (2013) Eculizumab for atypical hemolytic uremic syndrome in pregnancy. Obstet Gynecol 122:487–489CrossRefGoogle Scholar
Servais A, Devillard N, Frémeaux-Bacchi V et al (2016) Atypical hemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab. Nephrol Dial Transplant 31:2122–2130CrossRefGoogle Scholar
Burwick RM, Feinberg BB (2013) Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta 34:201–203CrossRefGoogle Scholar